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Abstract 
In this study, we have investigated the synthesis of nanoparticles of hydroxyapatite (HAp) and 
hydroxyapatite coated with chitosan (HAp/Ch) and the chitosan-poly-D,L-lactide-co-glycolide 
polymer blend (HAp/Ch-PLGA) as an organ-targeting system. We have examined and defined 
the final destination, as well as the dynamics and the pathways of the synthesized particles 
following intravenous administration in vivo.  
 The XRD, ZP, FT-IR and SEM analyses have confirmed that the hydroxyapatite nano 
particles with d50=72 nm are coated with polymers. Radioactive 125-Iodine (125I), a low energy 
gamma emitter, was used to develop a novel in situ method for the radiolabeling of particles and 
investigation of their biodistribution. 125I–labeled particles exhibited high stability in saline and 
serum over the second day, which justified their use in the following in vivo studies.  
--------------------------------------------------------------------  
* Author for correspondence (dragan.uskokovic@itn.sanu.ac.rs). 
The biodistribution of 125I-labeled particles after intravenous injection in rats differed 
significantly: HAp particles mostly targeted the liver, HAp/Ch the spleen and the liver, while 
HAp/Ch-PLGA targeted the lungs. Twenty-four hours post injection, HAp particles were 
excreted completely, while both 125I- HAp/Ch and 125I-HAp/Ch-PLGA were retained in the body 
for a prolonged period of time with more than 20% of radioactivity still found in different 
organs. 
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1. Introduction 
Nanoparticles based on hydroxyapatite (HAp) have many useful physicochemical and biological 
properties, such as an easy preparation and modification, as well as biocompatibility, which 
make them suitable for transport and unloading of various pharmaceuticals [1-3]. 
Nanoparticulate systems based on polymers or polymer-coated inorganic particles are a 
challenge for many research groups involved in designing materials for the replacement of 
tissues and other specific medical applications [4]. Hydroxyapatite nanoparticles coated with 
bioresorbable polymers have been successfully used as carriers of antibiotics, vitamins and stem 
cells in bone tissue engineering [5, 6]. Over the past few decades, different nanoparticulate 
platforms for targeted and temporal delivery have been studied for possible use in therapeutic 
applications [7]. Some researchers highlight the benefits of nanosystems ensuring local and 
controlled delivery of a drug compared to conventional systems, particularly in the regeneration 
of bone tissue [8]. There are various strategies of drug targeting, from passive to active targeting, 
dependening on the potential clinical application and the structure and properties of the system 
[9]. Interactions in the microenvironment of biomaterials and tissues are of a particular interest 
and present a challenge in regenerative nanomaterials engineering [10]. A study on targeted drug 
delivery can also be focused on the cell and its proteins [11]. The phenomena that influence the 
success of targeting and controlled operation or regenerative or therapeutic nanosystems are 
numerous and complex: size, shape, surface charge, functional groups of nanoparticles, electrical 
double-layer formation, zeta potential, isoelectric point of solid–liquid interface; receptor–ligand 
binding interactions of nano-bio interface etc [12]. 
 Chitosan is one of many natural biopolymers with a wide range of potential applications in 
regenerative medicine. Structurally, chitosan is a copolymer composed of randomly distributed 
β-(1→4)-linked D-glucosamine (GlcNH2) and N-acetyl-D-glucosamine (GlcNAc), obtained by 
the deacetylation of chitin, though the deacetylation is almost never complete [13]. Chitosan is 
considered one of the most valuable polymers for biomedical and pharmaceutical applications 
due to its biodegradability, biocompatibility, antimicrobial, non-toxicity and anti-tumor 
properties [14, 15]. The use of chitosan has proved to be reasonable in complex systems of 
targeted drug delivery in neurology [16]. Some researchers have focused on the unification of the 
desirable properties of HAp and chitosan and obtaining a hybrid system in order to improve the 
functionality of potential applications of such systems [17, 18]. Hybrid systems based on HAp 
and chitosan have shown an extremely rapid formation of a new bone and mineralization of a 
reconstructed bone defect [19]. In order to modify the properties of chitosan in the systems for 
controlled and targeted action, it was combined with poly-D,L-lactide-co-glycolide (PLGA) and; 
the research results indicate the validity of the applied concept [20, 21]. 
 In this study, we have examined the possibility of obtaining an organ-targeting carrier based 
on hydroxyapatite nanoparticles. The dependence of surface properties of small particles based 
on hydroxyapatite is studied: zeta potential, morphology, crystallinity/amorphousness and 
chemical groups, on their transport/pathways in the biological environment after intravenous 
administration. The subject of the study are nanoparticles of hydroxyapatite, uncoated and coated 
with chitosan and the chitosan-poly(DL-lactide-co-glycolide) blend. Radioactive iodine 125I was 
used for radiolabeling of newly synthesized particles in order to study their in vivo biological 
behavior. 
 
2. Experimental 
2.1 Synthesis of materials 
Aqueous calcium nitrate (Ca(NO3)2) solution (150 ml; 26.6wt%) was added to the solution of 
ammonium phosphate ((NH4)3PO4) (7 ml H3PO4 + 165 ml NH4OH + 228 ml H2O) at 50°C over 
the period of 60 minutes, while stirring at the rate of 100 rpm. The solution was then subjected to 
a heat treatment for 60 minutes at 100°C [22, 23]. The obtained gel was subjected to frozen 
vacuum drying at -10 to -60°C, under pressures between 0.37 and 0.1 mbar over the periods 
between one and four hours (Christ Alpha 1-2/LD Plus). The obtained product was 
hydroxyapatite powder (HAp).  
 Chitosan (Ch), of a low molecular weight (Aldrich, deacetylation>75%) dissolved in acetic 
acid (1 wt.%) was mixed with the HAp gel in the 4:6 mass ratio while stirring with a magnetic 
stirrer at 400 rpm. Distilled water was added drop-wise to the mixture of chitosan and HAp gel, 
while stirring at 21,000 rpm (Ultra-Turrax T25, IKA, Germany). The obtained mixture of 
chitosan and the HAp gel was slowly poured into glutaraldehyde solution (Grade I, 25% in H2O) 
at the speed of 21,000 rpm for one hour. The resulting mixture was then centrifuged at 5000 rpm 
and 5 °C for one hour (Hettich Universal 320R). The obtained powder was subjected to frozen 
vacuum drying at temperatures from −10 to −60 °C, under pressures between 0.37 and 0.1 mbar 
over the periods between one and six hours. The obtained product was the powder composed of 
chitosan-coated HAp particles (HAp/Ch).  
 PLGA (50:50, Sigma, USA) and chitosan dissolved in acetone and acetic acid were mixed 
with the HAp gel in the mass ratio of 2:2:6. Water solution of poloxamer 188 
(polyethylenepolypropylene glycol, 0.1 vol.%) was added drop-wise to the mixture of chitosan, 
PLGA and HAp gel, while stirring at 21,000 rpm. The obtained mixture of chitosan, PLGA and 
the HAp gel was slowly poured into glutaraldehyde solution (Grade I, 25% in H2O) at the speed 
of 21,000 rpm for one hour. The obtained mixture was then centrifuged at 500 rpm and 5 °C for 
one hour, and the obtained powder was subjected to frozen vacuum drying at −10 to −60 °C, and 
pressures from 0.37 mbar to 0.1 mbar for one to eight hours. The obtained product was the 
powder composed of HAp particles coated with chitosan-poly(D,L)-lactide-co-glycolide 
(HAp/Ch-PLGA). 
 
2.2 Characterization of the products 
X-Ray diffraction (XRD) was performed on a Philips PW-1050 diffractometer with Ni-filtered 
CuKα radiation. The scanning step was 0.02°. Electrokinetic parameters of the suspensions of 
synthesized particles were analyzed using a Zeta-Sizer Nano (Malvern Instruments Ltd.) in 
distilled water and pH 6.5. Infrared spectroscopy (FTIR) was done on a BOMEM MB-100 
spectrometer (Hartmann & Braun, Canada), using the KBr technique in the spectral range from 
400 to 4000 cm-1. The spectral resolution was 2 cm-1. The field-emission scanning electron 
microscopy (FE-SEM) measurements were performed on a MIRA 3 MXU (High resolution 
SEM, Tescan) microscope. The particle size distribution (PSD) was measured on 10 mg/ml of 
powders dispersed in water using a Mastersizer 2000 (Malvern Instruments Ltd.) and a HydroS 
dispersion unit for liquid dispersants. 
 
2.3 Labeling of HAp (HAp/Ch and HAp/Ch-PLGA) with 125I (in situ labeling) 
All radioactive materials were handled according to approved protocols at the Laboratory for 
radioisotopes, Vinca Institute of Nuclear Sciences. Na125I (Eγ = 35 keV, T1/2 = 60 days, carrier-
free) was purchased from Izotop (Budapest, Hungary) as a high concentration solution in 0.1M 
NaOH. HAp was radiolabeled with 125I by a modification of the chloramine T method [24] 
during their preparation and before the addition of chitosan or chitosan-poly(D,L)-lactide-co-
glycolide. 185 MBq of Na 125I was added to 10 mL of HAp suspension. The reaction was started 
by the addition of 0.2 mL of chloramine T (N-chloro-p-toluenesulfonamide (CAT), sodium salt, 
trihydrate; Merck, Darmstadt, Germany) solution (50 mg/mL, molar ratio HAp:CAT=4:1) in 
0.05M a phosphate buffer (pH 7.5). The mixture was tightly capped in the reaction flask and 
stirred for one hour at room temperature. The reaction was stopped by adding 0.3mL of sodium 
thiosulfate (100 mg/mL). The mixture was then centrifuged (at 10,000 rpm for 10 min) to 
precipitate 125I-labeled HAp. After the removal of the supernatant, the radiolabeled HAp 
obtained as a precipitate was subjected to further washings (for three times) to separate any 
unbound 125I. The 125I-activity of the supernatant and pellet were measured in a gamma counter 
(CompuGama 1282 LKB, Finland) using the manufacturer's settings for 125I. The labeling yield 
of the 125I-HAp was calculated as (radioactivity in pellet/total radioactivity before washes) 
x100%. Afterwards125I- labeled HAp was coated with chitosan or chitosan-poly(D,L)-lactide-co-
glycolide, according to the procedure described in 2.1 
  
2.4  In vitro stability studies  
In vitro stability of 125I- labeled HAp, HAp/Ch and HAp/Ch-PLGA was studied to determine any 
released 125I- activity from the radiolabeled particles in biological fluids during eight days. After 
125I-labeling suspensions of all three types of 125I-labeled nanoparticles (37 MBq) were 
centrifuged (at 10,000 rpm for 10 min). The supernatant was withdrawn and after addition of 3 
mL either saline (0.9% NaCl, pH=7.3) or human serum (National Blood Transfusion Institute, 
Belgrade, Serbia) samples were incubated by shaking at 37°C. At eight time points after the 
labeling (1-8 days), samples were centrifuged. Due to the risk of the withdrawal of 125I- labeled 
particles, the supernatant was not removed completely. Instead, an aliquot of 0.1 mL was 
carefully withdrawn from the supernatant and the radioactivity was measured separately in an 
aliquot and the remaining sample (pellet with labeled particles and 2.9 mL of supernatant).  The 
acquired radioactivity in the pellet was calculated as the difference between follows: the activity 
of the remainder and the activity of the supernatant (0.1 mL supernatant x 2.9). The in vitro 
stability of the labeled particles in biological fluids is expressed as a percentage of the particle-
associated radioactivity (radioactivity in the pellet) in relation to the total radioactivity in the 
sample. The experiments were done in triplicate. 
 2.5 Biodistribution studies 
The entire animal study conformed to ethical guidelines and the rules for animal care proposed 
by the Serbian Laboratory Animal Science Association (SLASA) and also complied with the 
Directive 2010/63/EU of the European Parliament and of the Council. Biodistribution studies of 
125I- labeled HAp were carried out in groups of five normal male Wistar rats (one month old, 
100–150 g in weight). An amount of 0.1 mL of the suspension of radiolabeled particles in saline 
contained 0.1 mg of 125I- labeled -HAp, -HAp/Ch or -HAp/Ch-PLGA (activity 2 MBq) was 
injected through the tail vein of each animal.  
The groups of rats were sacrificed at various time intervals (10min, 30min, 2h and 24h) post 
injection (p.i.) and blood and the tissues, including the heart, lungs, liver, spleen, kidney, 
stomach, intestine, muscles, femur and thyroid gland were harvested, weighed, and counted for 1 
min in a gamma counter. Standards were prepared and measured along with the samples, 
whereas the total counts injected per animal were calculated by the difference between the 
original syringe counts and the remaining syringe counts after injection. The uptake of the 
radiolabeled particles in each tissue sample was calculated as a fraction of the injected dose and 
was expressed as percentage injected dose per gram of tissue or organ (%ID/g).  
 
3. Results  
3.1 X-Ray diffraction (XRD) 
Figure 1 shows the diffractograms of HAp/Ch- PLGA, HAp/Ch, HAp and pure Ch and PLGA. 
The absence of the peaks in the diffractogram of PLGA indicates the amorphous nature of the 
polymer. Ch is defined with the diffractogram with two clearly marked peaks in the positions 
10.2° and 19.8°. The most intense peaks of HAp are on 31.8° (2 1 1), 32.2° (1 1 2), 32.9° (3 0 0), 
25.9° (0 0 2) and 49.5° (2 1 3). In accordance with the literature [25] and our previous studies 
[23], the HAp diffractogram obtained this way indicates poorly a crystalline form. The mean 
crystallite size (D) of the HAp powders calculated from the half-width (β1/2) of the XRD 
reflection of the (002) plane (2θ=25.9°) using the Scherrer equation was 11.8 nm.  
Figure 1. 
 
3.2 Zeta potential (ZP) measurements 
HAp particles have the value of -7.9±0.8, HAp/Ch +18.3±1.9 and HAp/Ch-PLGA +3.0±0.28. 
All values were measured in aqueous suspensions of particles at pH=6.5 and t=200C. 
 
3.3 FTIR spectroscopy analysis 
The IR spectra of HAp, Ch, PLGA, HAp/Ch and HAp/Ch-PLGA samples are shown in Fig. 2. 
and the following characteristic IR bands were identified on wavenumbers: ν(OH) 3600–3000 
cm–1 (HAp, PLGA, Ch; intensive, wide band), ν(NH2) 3500–3400 cm–1 (Chi; two bands, 
medium intensity, overlapped with a wide band of ν(OH)), ν(CH) 2900 cm–1 (HAp, PLGA, Ch; 
medium intensity), ν(C=O) 1755 cm–1 (PLGA; strong intensity), ν(C=O) 1655 cm–1 (amide I 
band, Ch; strong intensity), δ(HOH) approx. 1640 cm–1 (HAp, PLGA, Ch; weak to medium 
intensity), δ(NH) 1580 cm–1 (amide II band, Ch; medium intensity), δsy(CH) 1380 and δas(CH) 
1450 cm–1 (HAp, PLGA, Ch; weak to medium intensity), δ (OH) 1420 cm–1 (HAp, PLGA, Ch; 
medium intensity), ν(C–O) 1250–1050 cm–1 (PLGA, Ch; strong intensity), ν(C–N) 1320 cm–1 
(amide III band, Ch; medium intensity), ν(P=O) 1100 cm–1 (HAp; strong intensity), ν(P–O) 1030 
cm–1 (HAp; strong intensity overlapped with a band ν(P=O)), γ(CH) and γ(OH) 1000–700 cm–1 
(HAp, PLGA, Ch; weak intensity) [26]. In the area of approx. 860–875 cm–1, carbonate band 
appears from the carbonate substitution for hydroxyl and phosphate groups in hydroxyapatite 
[27]. 
Figure 2. 
 
3.4 Particle size distribution (PSD) 
The particle size distribution (PSD) of the synthesized HAp, HAp/Ch and HAp/Ch- PLGA are 
shown in Fig. 3. The average mass diameter d(0.5) or d50 which indicates that 50% of the 
particles are less than the specified value and 50% greater, amounts for HAp d50=70 nm, HAp 
/Ch d50=130 nm and HAp/Ch-PLGA d50=163 nm. The synthesized HAp particles have a 
uniform distribution, while the system HAp/Ch and HAp/Ch-PLGA shows the appearance of 
particle agglomerates of about 700 nm in diameter. 
Figure 3. 
 
3.5 Field-emission scanning electron microscopy (FE-SEM)  
The FE-SEM images of HAp, HAp/Ch and HAp/Ch-PLGA are shown in Fig. 4. By coating the 
particles of HAp with Ch, powders with spherical particles were obtained (Fig. 4b). The coating 
of HAp with a polymer blend Ch-PLGA also leads to the formation of particles with a spherical 
morphology (Fig. 4c). The results of the particle size distribution of HAp/Ch-PLGA (Fig. 3) with 
the possibility of forming agglomerates were confirmed with the existence of adhesion between 
individual particles (Fig. 4c). Quantitatively, the frequency of the formation of the HAp/Ch 
material agglomerate is not significant because only 10% of the fraction is greater than 820 nm 
(d90=820 nm). 
Figure 4. 
 
3.6 Labeling of HAp, HAp/Ch and HAp/Ch-PLGA with 125I 
In order to radiolabel particles with a specific radionuclide, two approaches can be used: the 
encapsulation of the radionuclide in the nanocarrier during the synthesis; and, after the synthesis 
of particles, direct incorporation of the radionuclide onto the particle surface or onto a chelator 
that is already attached to the particle surface. The labeling of particles after the preparation 
usually requires modification, such as amination of HAp for effective radioiodination [28]. In 
this study, all three types of HAp particles were radiolabeled with 125I during preparation of HAp 
before the addition of chitosan or chitosan-poly(D,L)-lactide-co-glycolide. Labeling without any 
modification was achieved by adding the oxidizing agent chloramines T in situ during the 
formation of HAp. This method resulted in the reproducible high labeling yield (78.2%) of 125I-
labeled HAp. Studies on the effect of the concentration of the oxidizing agent on the 
radiolabeling yield showed that the yield was significantly higher when the concentration of 
chloramines T was increased in the reaction mixture up to 10 mg, while it decreased significantly 
when chloramines T concentrations decreased above this. The radiolabeling yield was only 
12.5% when 2.5 mg of CAT was used (molar ratio HAp:CAT=1:1). The iodination of 
unmodified HAp after the preparation and during the preparation without the oxidizing agent 
chloramines T resulted in a complete absence of labeling. The variation of the pH of the reaction 
mixture showed that the optimum pH for radiolabeling was ~7.5-8, which is advantageous, as it 
is close to the physiological pH. The radiolabeling yield increased gradually with the incubation 
time and reached the optimum value after 60 min of incubation at room temperature. No 
differences in labeling yields were found between the three types of HAp after the addition of 
chitosan or chitosan-poly(D,L)-lactide-co-glycolide since the labeling step was completed during 
the formation of HAp.  
 
3.7 In vitro stability studies 
The in vitro stability of the labeled particles expressed as a percentage of the particle-associated 
radioactivity demonstrated the satisfactory stability of 125I-HAp both in saline and human serum 
(Fig. 5.). Radioactivity of the supernatant derived from the 125I released from 125I-labeled 
particles NPs. The in vitro stability studies in saline showed that 47±2% of 125I remained 
associated with uncoated HAp particles, while 71±3% and 83±2% remained associated with 
HAp coated chitosan and chitosan-poly(D,L)-lactide-co-glycolide, respectively, after eight days 
of incubation. Results of the in vitro stability in serum showed a similar trend: uncoated 125I-
HAp particles showed the lowest stability 42±1% after eight days of incubation, while 71±4% of 
125I-HAp/Ch and 78±3% of 125I-HAp/Ch-PLGA were stable to deiodination until the eighth day. 
Figure 5. 
 
3.8 Biodistribution studies of 125I-labeled HAp, -HAp/Ch and -HAp/Ch-PLGA 
The distribution patterns of 125I-HAp, 125I-HAp/Ch and 125I-HAp/Ch-PLGA in different tissues 
after 10 min, 30 min, 2 h and 24 h of intravenous administration in normal Wistar rats are shown 
in Fig. 6.  
Figure 6. 
 The applied radiolabeled HAp particles disappeared from the blood-stream relatively 
quickly and only 0.22 %ID/g of radioactivity remained in the blood  10 min p.i. The coating with 
polymers  prolonged the in vivo circulation of particles, resulting in the highest activity of 125I-
HAp/Ch in the blood 30 min p.i. (1.36%ID/g). 125I-HAp mainly accumulated in the liver 
(20.70%ID/g) during the initial time intervals (10 min). HAp/Ch were quickly taken up by the 
reticuloendothelial system (RES) of liver and spleen where they were almost equally distributed: 
11.04%ID/g in the liver and 14.41%ID/g in the spleen. However, almost 80%ID/g of the applied 
HAp/Ch-PLGA were localized in the lungs, much less in the liver (5.04 %ID/g) and in the spleen 
(1.88 %ID/g) 10 min after intravenous administration. The accumulated radioactivity 
immediately started to wash-out from the organs. Both coated 125I- HAp/Ch and 125I-HAp/Ch-
PLGA were excreted in the same amount (nearly 70%) through the hepatobiliary tract of the 
animals, while uncoated HAp was excreted completely in 24 h post application. There was no 
sign of radioactivity in the thyroid gland and stomach at any time, indicating the in vivo stability 
of all three types of 125I- HAp and the absence of the destruction of the labeled complex. These 
results are in good correlation with the results of significant in vitro stability of all three types of 
125I- HAp in the human serum. 
 
4. Discussion 
The absence of strong peaks in the diffractogram of PLGA indicates the amorphous nature of 
this polymer. The existence of two distinct peaks in the diffractogram of chitosan 2θ at 10.2° and 
19.7° indicates its high crystallinity, which is consistent with studies of other authors [29]. As it 
has been shown in our previous study, the diffraction pattern of HAp in Fig. 1 corresponds to 
poorly crystalline non-stoichiometric HAp [23]. The diffractograms of HAp/Ch and HAp/Ch-
PLGA samples (Fig. 1) indicate that the resulting material is made of HAp and Ch. In both 
diffractograms clear peaks originating from HAp and Ch are observed. According to the XRD 
studies performed on HAp/Ch systems by other authors, the peaks group at 2θ about 20° could 
indicate the intramolecular interaction between HAp and Ch and the formation of a hydrogen 
bond [17]. The less prominent characteristic peak of chitosan in the HAp/Ch and HAp/Ch-PLGA 
composite than in the pure Ch on 2θ at 19.7° may not be merely a consequence of the reduction 
of the share of Ch in the composite but also indicates the possibility that the crystallinity of Ch 
may be reduced during the process of the composite synthesis [30]. 
 It is known from literature data that HAp particles have negative values of the zeta potential 
[31, 32]. The coating of HAp with Ch, which has a positive zeta potential, is expected to result in 
a change of the surface properties and the reversal of the negative zeta potential to positive (Fig. 
2). When in a slightly acidic environment, chitosan enters the electrostatic interaction with the 
negatively charged environment due to the protonation of the free -NH2 groups [33]. The 
positive electric charge of chitosan and the potential of creating hydrogen bonds indicates its 
good adhesion properties in a biological environment [34] which may be of interest during the 
testing of these materials in vivo. The values of the zeta potential of PLGA, which depends on a 
number of factors (end groups of PLGA, surface charge density, type of stabilizing agent utilized 
during syntheis etc.), are all in the range of negative values. It is expected that HAp coated with 
Ch-PLGA has a lower value of the zeta potential than HAp coated only with Ch. The resultant 
trends are consistent with other studies focused on the analysis of the zeta potential of the Ch-
PLGA systems of different compositions [35, 36]. 
 The IR spectrum of the HAp/Ch composites sample is shown in Fig. 2. The IR spectrum is 
characterized by absorption bands arising from HAp and Ch, determined by analogy with the IR 
spectra of uncoated HAp and the same Ch standard samples (as illustrated in Fig. 2). The 
analysis of the FTIR spectrum in Fig. 2 reveals significant differences compared to the spectra of 
single-component materials. The sharp bands at 2923 and 2862 cm−1 are assigned to ν(CH) of 
the polysaccharide chitosan [37] and IR bands with maxima at 1087, 1033, 601 and 564 cm–1 
arise from the phosphate groups of HAp [38]. The formation of homogeneous Ch blends with 
HAp and PLGA is a result of strong interactions of hydrogen bonds between the functional 
groups of the blend components in which amino and amide groups present in Ch take part [39]. 
The analysis of the FTIR spectra of the blends enables us to identify these interactions. The 
broadening of the strong IR band at approx. 1087 cm−1, corresponding to the PO43−ions of HAp 
shows the presence of polysaccharide chitosan and its interaction with phosphate groups [40]. It 
implies that the hydrogen bonding may be formed between the phosphate groups and N–H of the 
Ch [41]. The peaks at 1655 cm−1, 1588 cm−1 and 1315 cm−1 are due to the amide I, amide II and 
amide III bands of polysaccharide chitosan. The band at 1655 cm−1 decreased and the band at 
1588 increased in Ch after the coating of HAp, indicating the interaction of the amide on the 
chitosan and OH groups on HAp. Considerably greater changes are observed in the spectrum of 
the HAp/Ch-PLGA composites sample. The IR spectrum of the sample of hydroxyapatite coated 
with the polymer blend of chitosan-poly(lactide-co-glycolide) (HAp/Ch-PLGA) is shown in Fig. 
2. The IR spectrum contains the already mentioned absorption bands arising from HAp, PLGA, 
Ch (as illustrated in Fig. 2). The specific IR bands of polysaccharide chitosan were observed at 
around 3500–3200 cm−1 for N–H stretching, at 2980–2880 cm−1 for C–H stretching, at 1737 cm–
1 for C=O stretching, at 1588 cm−1 for N–H bending, at 1500–1350 cm−1 for C–H bending and 
approx. 1310cm−1 for C–N stretching. A comparison of the FTIR spectra of HAp, PLGA and 
HAp/Ch-PLGA shows a specific peak shift due to the interaction of HAp with the polymer blend 
of Ch-PLGA. The differences in the FTIR spectra, i.e. the shift to lower wavenumbers and the 
narrowing of the vibration band from 1756 cm–1 to 1737 cm–1, which originates from ν(C=O), 
have been observed. This is probably due to the hydrogen bonding of C=O from PLGA with OH 
or NH2 from HAp or chitosan, which confirms their mutual interaction and particle formation. In 
the study of three-phase interactions in nano-hydroxyapatite/konjac glucomannan/chitosan 
composite amide I, the carbonyl stretching in Ch shifts to lower wavenumbers; this is attributed 
to the hydrogen bonding between the NH, C=O groups of konjacglucomannan/chitosan and OH 
from HAp [41]. The most significant differences in the FTIR spectra of HAp/Ch-PLGA 
compared to HAp/Ch are the increase in the band at 1588 (amide II) and the overlapping of the 
band at 1655 cm−1 (amide I) in the polymer blends of Ch-PLGA after the coating of HAp. This 
indicates the interaction of the amide on the chitosan and the OH groups on HAp. The 
appearance of new band, pronounced as a shoulder, at a lower frequency, approx. 3239 cm-1, 
which originates from the hydrogen bonded OH is due to the interactions between HAp and Ch-
PLGA. This is confirmed by the well-modified surface of the Ch-PLGA polymer blends after the 
coating of HAp. The addition of chitosan also affected the localized bonding structure of the 
phosphate groups in HAp, as seen from the broadening of the PO43− group bands [26]. The 1000–
700 cm–1 IR range is of special interest for structural investigations of polysaccharides and 
conformational changes, and both the number and frequencies of the bands in this IR range 
depend on the conformation of the D-glucopyranose units [42]. It is well known that the D-
glucopyranose units exist in six different typical conformations (1C, C1, 1B, B1, 3B and B3) [42, 
43]. The similarities of the γ(C–H) range indicate that there is no difference in the conformation 
of the GlcNH2 and GlcNAc units in the Ch, HAp/Ch and HAp/Ch-PLGA, and they probably 
exhibit C1 chair conformation (bands approx. 915 and 850 cm–1). As mentioned earlier [44], in 
β-D-glucans and their derivatives, only one most stable chair conformation C1 (4C1) of pyranose 
cycles is achieved and their mutual mobility is strongly limited. But in water, at equilibrium, 
GlcNAc undergoes a microsecond-timescale exchange between chair puckers (4C1 and 1C4), 
which is in good agreement with the NMR measurements and high-resolution crystallographic 
data for protein-bound GlcNAc ligands, where an appreciable number are not 4C1 conformers 
[45]. The results from literature [45] challenge the hypothesis that GlcNAc is a perfectly rigid 
4C1 chair, as predicted by high-level energy calculations without explicit water, straightforward 
interpretation of NMR data and non-equilibrium nanosecond-simulations. In the 1000–970 cm-1 
range, several bands are observed in the IR spectra of chitosan (approx. 1000, 993 and 984 cm-1). 
The appearance of these components is characteristic of polysaccharides with β-configuration of 
(1→4) glycosidic bond [46]. The ring deformations and scaffold vibrations for polysaccharide 
chitosan are observed at 705, 665, 605, 570, and 520 cm–1. 
 The uniform distribution of HAp particles is obtained (Fig. 3.) with d10=36nm, d50=70 nm 
and d90=156 nm. After the freeze-drying of the HAp/Ch powder, particles with the distribution 
of d10=66nm, d50=130 nm and d90=260 nm are obtained (Fig. 3.). It is assumed that the 
increase in the diameter of the obtained particles is due to the coating of HAp with Ch, but it is to 
a lesser degree also present in the appearance of the agglomerate, which is in accordance with 
the FE-SEM analysis (Fig. 4c). HAp/Ch-PLGA powder has a distribution of d10=73nm, d50 
=163 nm and d90=820 nm, indicating a trend of the increase in the average diameter of the 
particles in the sequence d(HAp) → d(HAp/Ch) → d(HAp/Ch-PLGA) and all fractions. HAp 
particles in all systems have the same diameter, and the increase in the diameter is the 
consequence of coating HAp with polymer and also of potential agglomeration. Agglomeration 
is more pronounced in the HAp/Ch-PLGA system, compared to HAp/Ch, which is expected, 
according to the results of the zeta potential. In accordance with the obtained values of d50, it 
was possible to presume the average thickness of the coatings: [d50(HAp/Ch)-d50(HAp)]/2∼30 
nm; [d50(HAp/Ch-PLGA)-d50(HAp)]/2∼47 nm. 
 In our previous research, we have demonstrated the possibilities and the mechanism of 
coating particles and small nano-sized agglomerates of HAp with bioresorbable polymers in the 
form of spheres [23, 47]. After two-stage emulgation procedure and subsequent processing in a 
centrifugal field, platet-like HAp is coated with Ch and spherical shapes are obtained (Fig. 4a, b), 
which is in accordance with XRD, ZP and FT-IR results. A similar morphology is observed in 
the system HAp/Ch-PLGA (Fig. 4c), except for the slightly larger diameter of the particles, 
which is also in accordance with the PSD results (Fig. 3.). Subsequent processing in the 
centrifugal field and the synthesis with a high energy emulsifier leads to obtaining a spherical 
particle morphology [47]. 
 As part of our ongoing effort to produce HAp vectors for different biomedical purposes, we 
have herein developed the efficient method for their radiolabeling with the aim of monitoring the 
biodistribution  of the synthesized particles. Due to their small size, it is a challenging task to 
track and detect particles in vivo. The in vivo behavior of HAp has not been reported extensively 
due to the lack of suitable tracking methods. Fluorescent labeling is achieved only for a short 
term, while qualitative findings and the inductively coupled plasma (ICP) spectrometry method 
hardly yield precise results due to the degradation of particles [48]. A promising technique for 
the following distribution of particles in biological systems is the use of radiotracers, due to the 
high sensitivity, accuracy and precision of radioactivity measurements. The choice of 
radionuclide depends on a number of characteristics including the type of particles, ease of 
preparation and the stability of radionuclide-particles conjugate as well as the availability, cost 
and the decay characteristics of the radionuclides [49]. The in vivo biodegradation processes and 
reversible isotope exchange processes can lead to instability and escape of radionuclides [50]; 
accordingly, the binding of the radionuclide to a nanoparticle has to be irreversible in order to 
prevent their release into the immediate environment. Also, the manufacturing process has to be 
fast and simple in order to decrease the risk of contamination. 90Y and 177Lu are a practical 
choice for labeling of HAp having in mind that by employing a simple technique HAp can be 
radiolabeled with these radionuclides in a very high yield. The key issues concerning the use of 
90Y are its physical and chemical characteristics and the biodistribution profile. As a pure β-
emitter, 90Y cannot be measured accurately by a standard gamma counter; it can only be detected 
by “bremsstrahlung”, so measurements by a standard gamma counter are not accurate [51, 52]. 
Also, the in vivo release of 90Y and 177Lu from the labeled particles would result in the 
misinterpretation of biodistribution results, especially in the studies where the same organs are 
targets both for these radionuclides and the labeled particles and their degradation products. 90Y 
and 177Lu in their ionic form have a high affinity for bone, while in colloidal form (after the 
dissociation from the labeled compounds in blood) they would be cleared through the liver [53]. 
Since most of the labeled particles accumulate in these organs, 90Y and 177Lu are not the ideal 
radionuclides for labeling of the studied particles.  
 125I is a readily available radionuclide with a low gamma-ray energy that can be used for 
tracking and quantifying in vivo. The circulating iodide is removed rapidly by both the thyroid 
gland and the stomach due to sodium iodide symporter (NIS)-mediated active transport. In other 
tissues, which do not express NIS, the uptake of sodium iodide is significantly lower than in 
NIS-expressing tissues and decreased over time, paralleling blood-pool clearance and excretion 
in the urine [54]. Since a misinterpretation of the biodistribution results of 125I-labeled particles is 
almost impossible due to the biodistribution of particles in NIS non-expressing tissues, 125I 
seems to be a good choice for the labeling of the investigated particles. Also, the labeling 
procedure optimized for the labeling of particles with 125I can be used for the labeling with beta 
emitting radionuclide 131I, ensuring a therapeutic effect. The present study describes for the first 
time the efficient radiolabeling of HAp with 125I in situ in the presence of an oxidant, such as 
chloramine-T. The radioiodination is probably based on the incorporation of some of the iodine 
species into the apatite lattice. Chloramine-T, ArSO2NClNa (Ar=CH3C6H4), behaves as an 
oxidizing agent in both acidic and alkaline media. The nature of active oxidizing species depends 
on the pH of the medium and the reaction conditions.  
ArSO2NHCl + OH–  ArSO2NH2 + ClO–  (1) 
I– + ClO- + OH-  OI/IO– → IO3–   (2) 
3HOI = IO3– + 2I– + 3H+   (3) 
In alkaline solutions, the predominant species of CAT are ArSO2NHCl and ClO– [Eq. (1)]. With 
a further increase in the alkalinity, the concentration of hypochlorite ions increases [55]. The 
iodide ion is oxidized by hypochlorite in the basic solution to hypoiodous acid (HOI), which can 
be deprotonated to hypoiodite (IO–) according to Eq. (2), and the equilibrium between the two 
species is established. Hypoiodite can be further oxidized to iodate (IO3–), whereas HOI can 
undergo rapid disproportionation to iodate and iodide (pH > 8) Eq. (3). These anions probably 
make coordination similar to carbonate anions on phosphate or hydroxide sites in the lattice. 
Since only small amounts of radioactive iodine were involved in radioiodination, the oxidized 
iodine species produced in the reaction with chloramine T could not influence crystal growth in 
HAp and other modifications in the HAp structure. This mechanism is more favorable than the 
intercalation of solvated/hydrated free iodide ions into molecular crystals of HAp. In aqueous 
solutions, sodium iodide typically dissociates to completion with the formation of free solvated 
ions. This method based on labeling without adding chloramine T did not result in the 
radioiodination of HAp and radiolabeling after the completion of the formation of HAp particles 
when iodine species could not enter the molecular crystal of HAp. The procedure used in this 
study allowed simple manipulations for labeling and purification and resulted in a highly 
efficient labeling yield (78%) of radiolabeled HAp particles. Therefore, the in vivo deiodination 
process was attenuated in two ways: by optimization of the labeling process and by washing of 
labeled HAp particles after the initial labeling until the most of 125I conjugated to the particles 
via labile physical adsorption had been eluted. Although this reduced the labeling yield, the in 
vitro and in vivo deiodination processes were also attenuated. 
 The in vitro stability studies (Fig.5.), have demonstrated that all three types of particles are 
stable and that they release less than 8 % of 125I from 125I-labeled nanoparticles in saline and 
serum until the second day, enabling in vivo studies during this period. The higher stability of 
both coated 125I-labeled-HAp/Ch and -HAp/Ch-PLGA over a week could be assigned to the 
protective effect of chitosan and polymers on the surface of HAp particles. The coated particles 
are probably less porous, thereby preventing the diffusion of 125I out and away from the particles. 
The accumulation of 125I in the thyroid and the stomach was negligible, indicating an in vivo 
stability of the radiolabeled particles.  
 The physical and chemical properties, including size, charge, and surface chemistry, greatly 
influence the pharmacokinetics and the tissue distribution of the particles [56]. Unlike small 
molecules that can diffuse through the capillary wall into the tissue, particles pass through the 
gaps between the cells of endothelium in certain tissues, such as tumors, liver, spleen or bone 
marrow [56]. Small HAp particles (~70 nm) easily penetrated through the endothelial wall in the 
liver (the pore size of liver fenestrae is 100 nm) resulting in the fast initial increase in the activity 
within this organ but poor retention. Regarding the tumor uptake, small particles behave 
similarly. They can easily pass through the leaky capillary wall in the tumor but can also be 
easily pushed out from the tumor into the blood. The results of the biodistribution of liposomes 
of different sizes have shown similar behavior as HAp particles. Liposomes smaller than 100 nm 
in size exhibit minimal spleen uptake, whereas an increase in particle size leads to an increase in 
the rate of spleen uptake [57].  
 Similarly to other nanomaterials, the in vivo pharmacokinetics and in vivo biodistribution of 
HAp particles are closely associated with their surface coatings. Beside the particle size (Fig 3.), 
the following parameters also significantly affect the in vivo particle distribution: zeta potential, 
the surface groups of coatings (Fig 2.) and the particle shape (Fig 4.). The clearance of 125I-HAp 
from the systemic circulation is very fast in the first 10 min after the intravenous injection. The 
coating with chitosan prolonged the circulation half-life of particles, so that an increased 
concentration of 125I-HAp/Ch in blood (almost seven times) 10 min p.i., as well as an extended 
circulation time was were revealed. When particles are intravenously administered, serum 
proteins also termed “opsonins”, bind on the particles which are recognized by the scavenger 
receptor on the macrophage cell surface and internalized, leading to a significant loss of particles 
from the circulation [58]. The accumulation of 125I-HAp/Ch mainly in the liver and spleen and a 
longer retention compared to the uncoated HAp particles are attributed to the endocytosis by 
macrophages of reticuloendothelial system (RES) of these tissues. A high accumulation of 
HAp/Ch-PLGA in the lungs indicates that particles were mechanically filtered by the capillary 
bed of the lungs. Therefore, the high accumulation of HAp/Ch-PLGA in the lungs probably 
occurred due to the aggregation of particles. Therewith, a small but detectable percentage (>0.1 
%) of 125I-HAp/Ch-PLGA was still circulating 24 h after the administration. The different 
uptakes of 125I-labeled-HAp/Ch and HAp/Ch-PLGA particles by the lungs and liver as well as 
the retention rate in these organs verify that physicochemical characteristics significantly affect 
the in vivo fate of particles.  
 
5. Conclusion 
The XRD, FT-IR and ZP analyses have confirmed that hydroxyapatite (HAp) particles with 
d50=70 nm are coated with chitosan (HAp/Ch) and the chitosan-poly-D,L-lactide-co-glycolide 
polymer blend (HAp/Ch-PLGA). The FTIR results of HAp/Ch and HAp/Ch-PLGA composites 
show the interaction between single components, which confirms strong interactions by 
hydrogen bonds between the functional groups of the blend components in which, amino and 
amide groups present in Ch take part. After the coating of HAp with Ch and Ch-PLGA, more 
round particle shapes were obtained compared to uncoated HAp.  
 It has been shown that the radiotracer technique with 125I-labeled HAp nanoparticles is a 
relevant approach to study the biodistribution of novel particles. The labeling method was 
optimized for 125I-labeling in situ, during the synthesis of particles. The in vitro studies in saline 
and human serum have revealed that 125I remains bound to particles for a period sufficient for a 
further in vivo application. HAp/Ch and HAp/Ch-PLGA particles exhibited rather different in 
vivo behaviors compared to uncoated HAp particles, after they had been intravenously injected. 
HAp particles mostly targeted liver, HAp/Ch spleen and liver and HAp/Ch-PLGA lungs. Along 
with the difference in targeting the final destination, the coated nanoparticles show different 
pharmacokinetics in terms of slower excretion compared to HAp. This study demonstrates that 
the composition of the coating of HAp nanoparticles determines their biodistribution properties, 
which has significant implications with regard to their application in controlled drug delivery and 
targeting. 
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Figure captions 
Figure 1. XRD analysis of HAp/Ch-PLGA, HAp/Ch, HAp, Ch and PLGA 
Figure 2. FTIR spectra of HAp, Ch, PLGA, HAp/Ch and HAp/Ch-PLGA samples 
Figure 3. PSD of HAp, HAp/Ch and HAp/Ch-PLGA 
Figure 4. FE-SEM micrographs of: a) HAp; b) HAp/Ch and c) HAp/Ch-PLGA 
Figure 5. In vitro stability of 125I-HAp, 125I-HAp/Ch and of 125I-HAp/Ch-PLGA in saline and 
human serum during eight days. The results are expressed as the percentage of the particle-
associated activity compared to the total radioactivity in medium 
Figure 6. Biodistribution of a) 125I-HAp (%ID/g+ S.D., n=5); b) 125I-HAp/Ch (%ID/g+ S.D., 
n=5); c) 125I-HAp/Ch-PLGA (%ID/g+ S.D., n=5) 
 










